Shop Apotheke Europe N.V. re-confirmed earnings guidance for 2022. For the full-year 2022, the Management Board expects to grow everything-but-Rx (non-Rx) sales by double-digits in the range of 15 to 25%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
133.8 EUR | +1.90% | +5.51% | +1.82% |
04-26 | REDCARE PHARMACY : Deutsche Bank reiterates its Buy rating | ZD |
04-26 | REDCARE PHARMACY : Hauck & Aufhauser keeps its Buy rating | ZD |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.82% | 2.86B | |
-33.90% | 14.89B | |
-25.06% | 12.2B | |
-28.07% | 6.54B | |
+13.39% | 6.37B | |
-9.19% | 6.03B | |
-0.44% | 4.73B | |
+59.80% | 4.57B | |
-9.15% | 3.82B | |
-10.72% | 3.51B |
- Stock Market
- Equities
- RDC Stock
- News Redcare Pharmacy NV
- Shop Apotheke Europe N.V. Re-Confirms Earnings Guidance for 2022